Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• RNA interference (RNAi) is a promising therapeutic strategy for cancer, offering high specificity against cancer-promoting genes.
• Loss of heterozygosity (LOH) in cancer cells creates genetic differences exploitable for targeted therapies.
• Single-nucleotide polymorphisms (SNPs) in essential genes affected by LOH can serve as therapeutic targets.

Purpose of the Study:

• To design and evaluate small interfering RNAs (siRNAs) targeting the POLR2A gene, located near the frequently LOH tumor suppressor gene p53.
• To investigate the genotype-specific inhibition of POLR2A expression and its effect on cancer cell proliferation and tumor growth.

Main Methods:

• Design of siRNAs targeting the POLR2A gene, considering single-nucleotide polymorphisms (SNPs).
• In vitro assessment of siRNA-mediated inhibition of POLR2A expression based on genotype.
• In vivo evaluation of siRNA efficacy in inhibiting cancer cell proliferation and tumor growth in nude mice, analyzing genotype dependency.

Main Results:

• In vitro studies confirmed that siRNA can selectively inhibit POLR2A expression in a genotype-dependent manner.
• Cancer cell proliferation and tumor growth in nude mice were significantly inhibited in a genotype-dependent fashion.
• The results indicate that targeting SNPs in POLR2A with siRNA can selectively affect cancer cells with LOH.

Conclusions:

• siRNA-mediated targeting of SNPs in the POLR2A gene represents a viable strategy for genotype-specific cancer therapy.
• This approach offers a novel method for inhibiting tumor growth by exploiting genetic differences in cancer cells.
• The findings support the potential of siRNA as an adjunct to conventional chemotherapy for cancer treatment.